• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

  • Home
  • Expertise
    • Real-World Evidence
    • Non-interventional study design
    • Post-authorization safety studies
    • Post-authorization efficacy studies
    • Cohort studies
    • Case-control studies
    • Medical Devices
    • Diagnostic tools
      • Research team
    • Data collection instruments
  • Services
    • RWE Services
    • Crisis Management
    • Consulting
    • Data Management and Biostatistics
    • Medical Writing
    • Study Management
    • Quality Assurance
    • Pharmacovigilance
  • Library & News
    • News/Conferences
    • Publications
  • About Us
    • Who We Are
      • Management Board
      • Executive Team
      • Project Management Team
    • History
    • Careers
    • Data Protection Information
  • Contact

Internal structure of the SHE

A paper-based scale for patient-reported outcomes.

The format of the SHE scale was designed as paper-based scale. A Likert scale (1-5) was used to describe the personally perceived severity (or intensity) of the complaints (items). All items were phrased in a negative direction (complaints).  Two examples of how to complete the questionnaire are provided at the beginning of the scale in order to familiarize women with the questionnaire process.

The raw scale (90 items) was structured in five sections: “complaints/symptoms” (43 items), “use of hormones” (12 items), “reproductive history” (3 items), “lifestyle markers and demographic” (10 items), and “conditions/diseases” (22 items). The latter sections were deemed necessary for the interpretation of the structural (factorial) analysis  and for a meaningful item selection process.

Based on the information gathered during initial testing, the questionnaire was shortened and simplified to 43 items.  Below this point the extrinsic and intrinsic validity became compromised.

 

Five domains assessing sex hormone-related complaints

Five, theoretically independent dimensions (domains), were identified during the development and testing period; ‘sexual problems [SEX]’, ‘menstrual problems [MENS]’, ‘hormonal effects [HORM]’, ‘psychological problems [PSYCH], and ‘abdominal complaints [ABDOM]’. The factor solution for the 15-tem scale explained 66.1% of the total variance in the database, which is considered as good result.

  • Domain 1: ‘Sexual problems’ (SEX): 15% of total variance
  • Domain 2: ‘Menstrual problems’ (MENS): 14.8% of total variance
  • Domain 3: ‘Hormonal effects’ (HORM): 14% of total variance
  • Domain 4: Psychological problems’ (PSYCH):13.2% of total variance
  • Domain 5: ‘Abdominal complaints (ABDOM): 9% of total variance

The final SHE scale was validated in a German observational study of 108 women aged 26- 60 years. The German factorial analysis showed very similar results as seen in the development phase.  A slightly higher percentage of the total variance was explained by the five domains in the German sample (73.3% and 66.1% in the German and Italian sample, respectively). Again, the same 5 domains were extracted in the factorial analysis and the factor loadings were very similar if not identical with the Italian sample.

sidebar

Short Term Hormone Effect Scale

  • About SHE
  • Languages
  • Development of the scale
  • Internal structure of the SHE
  • Psychometric characteristics
  • Implementation and Scoring
  • References

To All Diagnostic Tools

sidebar-alt

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Invalidenstraße 115
10115 Berlin
Germany

Contact Us

Services

  • Crisis Management
  • Consulting
  • Data Management and Biostatistics
  • Medical Writing
  • Study Management
  • Quality Assurance
  • Pharmacovigilance

ENCePP

We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

General Data Protection Regulation

With a view to the introduction of the GDPR/EUDSGVO we are glad to present our newupdated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.

© 2011–2023 ZEG Berlin

Impressum

Website by Laura Yeffeth.